Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

SUDO Kazuki (Depertment of Medical Oncology)

SUDO Kazuki

SUDO Kazuki MD, PhD 

Dr. SUDO's story

Through my experience at the MD Anderson Cancer Center and the National Cancer Center Japan, I have met many cancer researchers and oncologists from many countries. I believe that a wide range of international collaboration is essential to promote cancer research. Cancer care is advancing day by day.  Our team will work to establish and promote cancer research network in Asia and contribute to improve cancer treatment in Asia.

Research interests

Since I came to National Cancer Center, I have expanded my research to include clinical trial and translational research. I am participating in phase 2 and phase 3 clinical trials at the medical oncology department and early drug development at the phase 1 unit.  I currently serve as head of The International Translational Research section at  National Cancer Center Hospital and work on genomics research.

Professional Experiences

  • 2020-present Head of Physician at Dept. of Medical Oncology at NCCH, Head of The International Translational Research section at Dept. of International Clinical Development at NCCH.
  • 2019-present Concurrent appointment at the Dept. of Experimental Therapeutics, NCCH.
  • 2017-2020 Staff physician, Dept. of Breast and Oncology at NCCH and Rare Cancer Center
  • 2012-2014 Postdoctoral Fellow (Research), Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
  • 2006-2012 Resident and Chief resident, GI surgery, St. Luke's International Hospital.

Selected publications

  1. K Sudo, K Kato, J Matsuzaki, S Takizawa, Y Aoki, H Shoji, S Iwasa, Y Honma, A Tma, H Sakamoto, T Naka, S Sekine, N Boku, T Ochiya. Identification of serum microRNAs predicting the response of esophageal squamous-cell carcinoma to nivolumab. Japanese journal of clinical oncology. 2020;50 (2), 114-121.
  2. K Sudo, K Kato, J Matsuzaki, N Boku, S Abe, Y Saito, H Daiko, S Takizawa, Y Aoki, H Sakamoto, S Niida, F Takeshita, T Fukuda, T Ochiya. Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling. JAMA Netw Open. 2019;2(5):e194573. doi:10.1001/jamanetworkopen.2019.4573.
  3. A Hirakawa, K Sudo, K Yonemori, R Sadachi, F Kinoshita, Y Kobayashi, HS Okuma, A Kawachi, K Tamura, Y Fujiwara, L Rubinstein, N Takebe. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clinical Pharmacology & Therapeutics. 2019;106 (4), 803-809.
  4. K Sudo, X Wang, L Xiao, R Wadhwa, H Shiozaki, E Elimova, DC Rice, JH Lee, B Weston, MS Bhutani, A Hiremath, N Charalampakis, R Komaki, MA Blum, SG Swisher, DM Maru, HD Skinner, JL Garris, JE Rogers, WL Hofstetter, JA Ajani. A nomogram to predict distant metastases after multimodality therapy for patients with localized esophageal cancer. Journal of the National Comprehensive Cancer Network.: JNCCN. 2016;14(2):173-179.
  5. K Sudo, L Xiao, R Wadhwa, H Shiozaki, E Elimova, T Taketa, MA Blum, JH Lee, MS Bhutani, B Weston, WA Ross, R Komaki, DC Rice, SG Swisher, WL Hofstetter, DM Maru, HD Skinner, JA Ajani. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. Journal of Clinical Oncology. 2014;32 (30), 3400.
  6. HD Skinner, JH Lee, MS Bhutani, B Weston, W Hofstetter, R Komaki, H Shiozaki, R Wadhwa, K Sudo, E Elimova, S Song, Y Ye, M Huang, J Ajani, X Wu. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 2014;120 (23), 3635-3641.
  7. JA Ajani, X Wang, S Song, A Suzuki, T Taketa, K Sudo, R Wadhwa, WL Hofstetter, R Komaki, DM Maru, JH Lee, MS Bhutani, B Weston, V Baladandayuthapani, Y Yao, S Honjo, AW Scott, HD Skinner, RL Johnson, D Berry. ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Molecular oncology. 2014;8 (1), 142-149.
  8. S Song, JA Ajani, S Honjo, DM Maru, Q Chen, AW Scott, TR Heallen, L Xiao, WL Hofstetter, B Weston, JH Lee, R Wadhwa, K Sudo, JR Stroehlein, JF Martin, MC Hung, RL Johnson. Hippo coactivator YAP1 upregulates SOX9 and endows stem-like properties to esophageal cancer cells. Cancer Res. 2014;74 (15), 4170-4182.
  9. NKS Cheedella, A Suzuki, L Xiao, WL Hofstetter, DM Maru, T Taketa, K Sudo, MA Blum, SH Lin, J Welch, JH Lee, MS Bhutani, DC Rice, AA Vaporciyan, SG Swisher, JA Ajani. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Annals of oncology. 2013;24 (5), 1262-1266.
  10. K Sudo, T Taketa, AM Correa, MC Campagna, R Wadhwa, MA Blum, R Komaki, JH Lee, MS Bhutani, B Weston, HD Skinner, DM Maru, DC Rice, SG Swisher, WL Hofstetter, JA Ajani. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. Journal of clinical oncology. 2013;31 (34), 4306.